Dr Reddy's Q1 Results

PAT jumps 1,257% sequentially to Rs. 1,188 cr

In India, revenue was Rs. 13.3 billion, up 26 percent year on year, thanks to the disposal of a few non-core companies.

In Q1FY23, consolidated income from operations was Rs. 5,215.4 crore, up 6% from Rs. 4,919.4 crore in Q1FY22 but down 4.07% from Rs. 5,436.8 crore in Q4FY22.

Dr Reddy's Laboratories reported a multi-fold increase in bottom-line revenue for the fiscal quarter ended June 30, 2022 (Q1FY23).

In Q1FY23, the company reported a consolidated net profit of Rs. 1,187.6 crore, up 108.05 percent from Rs. 570.8 crore in the same period last year.

However, Q1 PAT increased by a staggering 1,257.25% from Rs. 87.5 crore in the previous quarter.

Profits were boosted by a few non-recurring earnings, which countered the short-term difficulties.

According to the pharmaceutical company, revenues increased by 6% during the quarter to Rs 5,215.4 crore, up from Rs 4,919.4 crore in the first quarter of FY22.

Furthermore, other operating revenue was Rs 600 crore, up from Rs 50 crore in QlFY22.

IT Stocks

in India

The IT Sector or Information Technology Sector in India is booming. As per reports by IBEF the IT Industry accounts for 8% of India’s GDP.

Top 10